For instance, KRASG12C mutations are rare in pancreatic cancer (2–3% of all KRAS mutations) and CCA (8%) but represent the predominant KRAS mutation subtype in NSCLC (39–42%) [140]. This evidence concerns the gene KRAS and cholangiocarcinoma.